A comparison of esmolol and diltiazem for heart rate control during coronary revascularisation on beating heart

S Chauhan1, N Saxena, B H Rao

  • 1Department of Cardiac anaesthesia and Cardiac Surgery Cardiothoracic Centre, All India Institute of Medical Sciences, New Delhi, India. sancha@medinst.ernet.in.

Insights

Esmolol provided superior heart rate control during coronary artery revascularization surgery but increased pulmonary artery pressure. Diltiazem offered hemodynamic benefits, making it potentially better for hypertensive patients.

Area of Science:

  • Cardiovascular Surgery
  • Anesthesiology
  • Pharmacology

Background:

  • Coronary artery revascularization without cardiopulmonary bypass requires precise hemodynamic management.
  • Controlling heart rate and blood pressure is crucial during surgical anastomosis.

Purpose of the Study:

  • To compare the efficacy of esmolol and diltiazem in controlling heart rate and hemodynamics during off-pump coronary artery revascularization.
  • To evaluate the safety and potential adverse effects of each agent in this surgical context.

Main Methods:

  • Prospective study of 60 adult patients with coronary artery disease undergoing off-pump revascularization.
  • Randomized groups: Group A received esmolol (loading dose 50 microg/kg, infusion 100 microg/kg/hr); Group B received diltiazem (loading dose 0.15 mg/kg, infusion 5 mg/hr).
  • Hemodynamic parameters including heart rate, systemic vascular resistance, and pulmonary artery pressures were monitored.

Main Results:

  • Esmolol group achieved significantly better heart rate control (51.4 beats/min) compared to diltiazem (69.6 beats/min) (p <0.01).
  • Esmolol caused significant increases in mean pulmonary artery pressure and pulmonary vascular resistance.
  • Diltiazem decreased systemic vascular resistance, mean pulmonary artery pressure, and pulmonary artery wedge pressure, with a reduced right ventricular stroke work index.

Conclusions:

  • Esmolol offers superior heart rate reduction but necessitates caution due to potential pulmonary hypertension, especially in patients with right ventricular dysfunction.
  • Diltiazem may be a preferable option for hypertensive patients undergoing off-pump coronary revascularization due to its favorable systemic hemodynamic effects.

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...